Literature DB >> 23494411

Multiple splice variants of EWSR1-ETS fusion transcripts co-existing in the Ewing sarcoma family of tumors.

Barbara Patócs1, Krisztina Németh, Miklós Garami, Gabriella Arató, Ilona Kovalszky, Miklós Szendrői, György Fekete.   

Abstract

PURPOSE: The Ewing sarcoma family of tumors (EFT) is characterized by fusions of the EWSR1 gene on chromosome 22q12 with either one of the genes encoding members of the ETS family of transcription factors, in the majority of cases FLI1 or ERG. Many alternative EWSR1-ETS gene fusions have been encountered, due to variations in the locations of the EWSR1 and ETS genomic breakpoints. The resulting heterogeneity in EWSR1-ETS fusion transcripts may further be increased by the occurrence of multiple splice variants within the same tumor. Here we present a retrospective study designed to detect all of the EWSR1-FLI1 and EWSR1-ERG fusion transcripts in a series of 23 fresh frozen EFT tissues.
METHODS: RT-PCR and nested fluorescent multiplex PCR were used to amplify EWSR1-FLI1 and EWSR1-ERG transcripts from EFT tissues. Fusion transcripts were identified by laser-induced fluorescent capillary electrophoresis and confirmed by sequence analysis.
RESULTS: Nine different EWSR1-FLI1 fusion transcripts and one EWSR1-ERG fusion transcript were identified in 21 out of 23 fresh frozen EFT tissue samples. In five cases multiple fusion transcripts were found to coexist in the same tumor sample. We additionally reviewed previous reports on twelve cases with multiple EWSR1-ETS fusion transcripts.
CONCLUSIONS: Alternative splicing may frequently affect the process of EFT-associated fusion gene transcription and, as such, may significantly contribute to the pathogenic role of EFT-associated chromosome translocations. In a considerable number of cases this may result in multiple splice variants within the same tumor.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23494411     DOI: 10.1007/s13402-013-0126-8

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  37 in total

1.  A novel EWS-ERG rearrangement generating two hybrid mRNAs in a peripheral primitive neuroectodermal tumour (pPNET) with a t(15;22) translocation.

Authors:  F Minoletti; G Sozzi; S Tornielli; S Pilotti; A Azzarelli; M A Pierotti; P Radice
Journal:  J Pathol       Date:  1998-12       Impact factor: 7.996

2.  The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology.

Authors:  Károly Szuhai; Marije Ijszenga; Danielle de Jong; Apollon Karseladze; Hans J Tanke; Pancras C W Hogendoorn
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

3.  A new member of the ETS family fused to EWS in Ewing tumors.

Authors:  M Peter; J Couturier; H Pacquement; J Michon; G Thomas; H Magdelenat; O Delattre
Journal:  Oncogene       Date:  1997-03-13       Impact factor: 9.867

4.  A novel chimera gene between EWS and E1A-F, encoding the adenovirus E1A enhancer-binding protein, in extraosseous Ewing's sarcoma.

Authors:  F Urano; A Umezawa; W Hong; H Kikuchi; J Hata
Journal:  Biochem Biophys Res Commun       Date:  1996-02-15       Impact factor: 3.575

5.  A novel t(4;22)(q31;q12) produces an EWSR1-SMARCA5 fusion in extraskeletal Ewing sarcoma/primitive neuroectodermal tumor.

Authors:  Janos Sumegi; Jun Nishio; Marilu Nelson; Robert W Frayer; Deborah Perry; Julia A Bridge
Journal:  Mod Pathol       Date:  2010-11-26       Impact factor: 7.842

6.  Utilisation of fluorescent multiplex PCR and laser-induced capillary electrophoresis for the diagnosis of Ewing family of tumours in formalin-fixed paraffin-embedded tissues.

Authors:  Barbara Patócs; Krisztina Németh; Miklós Garami; Gabriella Arató; Ilona Kovalszky; Miklós Szendroi; György Fekete
Journal:  J Clin Pathol       Date:  2012-09-26       Impact factor: 3.411

7.  Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial.

Authors:  Marie-Cecile Le Deley; Olivier Delattre; Karl-Ludwig Schaefer; Sue A Burchill; Gabriele Koehler; Pancras C W Hogendoorn; Thomas Lion; Christopher Poremba; Julien Marandet; Stelly Ballet; Gaelle Pierron; Samantha C Brownhill; Michaela Nesslböck; Andreas Ranft; Uta Dirksen; Odile Oberlin; Ian J Lewis; Alan W Craft; Heribert Jürgens; Heinrich Kovar
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

8.  A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1.

Authors:  I S Jeon; J N Davis; B S Braun; J E Sublett; M F Roussel; C T Denny; D N Shapiro
Journal:  Oncogene       Date:  1995-03-16       Impact factor: 9.867

9.  Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients?

Authors:  A Zoubek; B Dockhorn-Dworniczak; O Delattre; H Christiansen; F Niggli; I Gatterer-Menz; T L Smith; H Jürgens; H Gadner; H Kovar
Journal:  J Clin Oncol       Date:  1996-04       Impact factor: 44.544

10.  Undifferentiated small round cell sarcomas with rare EWS gene fusions: identification of a novel EWS-SP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions.

Authors:  Lu Wang; Rohit Bhargava; Tao Zheng; Leonard Wexler; Margaret H Collins; Diane Roulston; Marc Ladanyi
Journal:  J Mol Diagn       Date:  2007-08-09       Impact factor: 5.568

View more
  8 in total

1.  Osteosarcoma With Apparent Ewing Sarcoma Gene Rearrangement.

Authors:  Melissa D Mathias; Alexander J Chou; Paul Meyers; Neerav Shukla; Meera Hameed; Narasimhan Agaram; Lu Wang; Michael F Berger; Michael Walsh; Alex Kentsis
Journal:  J Pediatr Hematol Oncol       Date:  2016-07       Impact factor: 1.289

2.  Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.

Authors:  Patrick J Grohar; Suntae Kim; Guillermo O Rangel Rivera; Nirmalya Sen; Sara Haddock; Matt L Harlow; Nichole K Maloney; Jack Zhu; Maura O'Neill; Tamara L Jones; Konrad Huppi; Magdalena Grandin; Kristen Gehlhaus; Carleen A Klumpp-Thomas; Eugen Buehler; Lee J Helman; Scott E Martin; Natasha J Caplen
Journal:  Cell Rep       Date:  2016-01-14       Impact factor: 9.423

3.  Primary paraesophageal Ewing's sarcoma: an uncommon case report and literature review.

Authors:  Noelia Tarazona; Lara Navarro; Juan Miguel Cejalvo; Valentina Gambardella; J Alejandro Pérez-Fidalgo; Alejo Sempere; Samuel Navarro; Andrés Cervantes
Journal:  Onco Targets Ther       Date:  2015-05-14       Impact factor: 4.147

Review 4.  Fusion transcripts: Unexploited vulnerabilities in cancer?

Authors:  Carla Neckles; Soumya Sundara Rajan; Natasha J Caplen
Journal:  Wiley Interdiscip Rev RNA       Date:  2019-08-13       Impact factor: 9.957

5.  Splice variants denote differences between a cancer stem cell side population of EWSR1‑ERG‑based Ewing sarcoma cells, its main population and EWSR1‑FLI‑based cells.

Authors:  Eberhard Korsching; Julian Matschke; Marc Hotfilder
Journal:  Int J Mol Med       Date:  2022-01-28       Impact factor: 4.101

6.  One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma.

Authors:  Guillermo Flores; Patrick J Grohar
Journal:  J Bone Oncol       Date:  2021-12-01       Impact factor: 4.072

7.  mRNA Capture Sequencing and RT-qPCR for the Detection of Pathognomonic, Novel, and Secondary Fusion Transcripts in FFPE Tissue: A Sarcoma Showcase.

Authors:  Anneleen Decock; David Creytens; Steve Lefever; Joni Van der Meulen; Jasper Anckaert; Ariane De Ganck; Jill Deleu; Bram De Wilde; Carolina Fierro; Scott Kuersten; Manuel Luypaert; Isabelle Rottiers; Gary P Schroth; Sandra Steyaert; Katrien Vanderheyden; Eveline Vanden Eynde; Kimberly Verniers; Joke Verreth; Jo Van Dorpe; Jo Vandesompele
Journal:  Int J Mol Sci       Date:  2022-09-20       Impact factor: 6.208

8.  Gene expression profiling of peripheral blood cells: new insights into Ewing sarcoma biology and clinical applications.

Authors:  Joanna Przybyl; Katarzyna Kozak; Hanna Kosela; Slawomir Falkowski; Tomasz Switaj; Iwona Lugowska; Anna Szumera-Cieckiewicz; Konrad Ptaszynski; Beata Grygalewicz; Magdalena Chechlinska; Barbara Pienkowska-Grela; Maria Debiec-Rychter; Janusz A Siedlecki; Piotr Rutkowski
Journal:  Med Oncol       Date:  2014-07-10       Impact factor: 3.064

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.